1. Home
  2. RYTM vs ACIW Comparison

RYTM vs ACIW Comparison

Compare RYTM & ACIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • ACIW
  • Stock Information
  • Founded
  • RYTM 2008
  • ACIW 1975
  • Country
  • RYTM United States
  • ACIW United States
  • Employees
  • RYTM N/A
  • ACIW N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • ACIW EDP Services
  • Sector
  • RYTM Health Care
  • ACIW Technology
  • Exchange
  • RYTM Nasdaq
  • ACIW Nasdaq
  • Market Cap
  • RYTM 4.3B
  • ACIW 5.1B
  • IPO Year
  • RYTM 2017
  • ACIW 1995
  • Fundamental
  • Price
  • RYTM $61.99
  • ACIW $44.59
  • Analyst Decision
  • RYTM Strong Buy
  • ACIW Strong Buy
  • Analyst Count
  • RYTM 12
  • ACIW 5
  • Target Price
  • RYTM $76.75
  • ACIW $60.00
  • AVG Volume (30 Days)
  • RYTM 525.0K
  • ACIW 628.8K
  • Earning Date
  • RYTM 08-05-2025
  • ACIW 07-31-2025
  • Dividend Yield
  • RYTM N/A
  • ACIW N/A
  • EPS Growth
  • RYTM N/A
  • ACIW 87.47
  • EPS
  • RYTM N/A
  • ACIW 2.53
  • Revenue
  • RYTM $136,863,000.00
  • ACIW $1,672,834,000.00
  • Revenue This Year
  • RYTM $37.56
  • ACIW $9.14
  • Revenue Next Year
  • RYTM $74.99
  • ACIW $6.78
  • P/E Ratio
  • RYTM N/A
  • ACIW $17.50
  • Revenue Growth
  • RYTM 48.88
  • ACIW 13.11
  • 52 Week Low
  • RYTM $39.46
  • ACIW $35.99
  • 52 Week High
  • RYTM $69.89
  • ACIW $59.71
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 47.67
  • ACIW 33.45
  • Support Level
  • RYTM $60.70
  • ACIW $44.96
  • Resistance Level
  • RYTM $62.65
  • ACIW $47.93
  • Average True Range (ATR)
  • RYTM 2.39
  • ACIW 0.99
  • MACD
  • RYTM -0.52
  • ACIW -0.06
  • Stochastic Oscillator
  • RYTM 14.04
  • ACIW 9.92

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About ACIW ACI Worldwide Inc.

ACI Worldwide Inc develops, markets and installs a portfolio of software products focused on facilitating electronic payments. The firm also leverages its distribution network in the Americas; Europe, the Middle East, and Africa, or EMEA; and Asia-Pacific regions to sell software developed by third parties. ACI software products process payment transactions for retail banking clients, billers such as utilities and healthcare providers, and community banks and credit unions. ACI's customers are financial institutions all over the world, but majority of the revenue is generated in the United States and EMEA regions.

Share on Social Networks: